Goodwin advised Royalty Pharma on its agreement to buy tiered, sales-based royalty rights on the global net sales of sacituzumab govitecan from Immunomedics for $175 million….
Royalty Pharma and Immunomedics’ $250 Million Royalty Funding and Stock Purchase Agreements
